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Background: Pandemic flu had at least two waves in Iran. Knowing how many of the 
general population were already exposed to this infection has a major impact on na-
tional preventive measures. As of December 30, 2009, a total of 3672 confirmed cases 
of human infection with a novel Influenza A (2009 H1N1) virus had been reported in 
Iran with 140 deaths. Objective: In this study we aim to measure, as a pilot study, the 
seroprevalence of positive antibody titer (humoral immunity) against 2009 H1N1 virus 
in Iranian population in Shiraz, Southern Iran. Methods: Through cluster random sam-
pling of families residing in Shiraz, 2553 subjects were selected and after a medical  in-
terview blood samples were taken and checked for polyclonal antibody against 2009 
H1N1 antigen using hemagglutination inhibition assay. An antibody titer of more than 
1:40 dilution was considered positive. Data were analyzed considering the demographic 
characteristics of the population and were compared among different age groups.  
Results: 1504 (58.91%) samples were tested positive for the presence of polyclonal an-
tibody against 2009 H1N1 virus. The prevalence of positive titers were significantly 
higher in 60 to 64 years old group and significantly lower in 20 to 24 years old group 
(p<0.05). Data did not differ based on other demographic characteristics or the history 
of flu like illnesses in the past 6 months. Conclusion: High seroprevalence of antibody 
against 2009 H1N1 in the sera of our subjects describes either a high level of pre-
existing immunity against H1N1 in Iranian population or a high rate of asymptomatic 
infection in our area compared to other countries. 
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INTRODUCTION  
 
With the first reports of unusual respiratory illness in Mexico and the United States by 
the end of April 2009, a novel influenza A (2009 H1N1) virus has spread globally 
among humans. This virus consists of specific combinations of gene segments from 
both North American and Eurasian swine lineages. It has antigenic distinction from sea-
sonal human influenza A and has not been identified till now in either swine or human 
populations (1). 
With the worldwide progression of the disease, World Health Organization (WHO) of-
ficially declared it as influenza pandemic on June 11, 2009 (2). As of December 30, 
2009, a total of 3672 confirmed cases of human infection with a novel influenza A 
(2009 H1N1) virus has been reported in Iran with 140 deaths (3).  
The swine originated influenza virus (S-OIV) hemagglutinin differs genetically and an-
tigenically from hemagglutinins of contemporary human seasonal H1N1 influenza vi-
ruses. At the beginning of the pandemic around the world, there was a fear that little 
protective immune memory exists in the general human population. This concern was 
confirmed by surveys demonstrating that the neutralizing antibodies against S-OIV can 
be found almost exclusively in those born before 1957, probably because of their expo-
sure to H1N1 influenza strains that did not circulate after that time (4). Also regardless 
of significant mortality rate in Mexico and USA at the beginning of the disease progres-
sion, pandemic flu has caused mild symptoms, with mortality rate remaining at 0.45% (5). 
Hemagglutination Inhibition (HI) assay has long been proposed as a standard method 
for detection of antibody against influenza virus antigen. Influenza virus agglutinates 
erythrocytes through the interaction of the virus surface glycoprotein, the hemaggluti-
nine (HA), with receptors on the surface of the erythrocytes. If viral particles are suffi-
cient in quantity, the interaction of HA protein with erythrocytes will form a complete 
network of linked erythrocytes and will prevent them from precipitation. 
The basis of hemagglutination assay is agglutination of erythrocytes and inhibition of 
the agglutination reaction by HA subtype specific antisera is the basis of the hemagglu-
tination inhibition (HI) assay (6-8). 
At the beginning of policy making for vaccination strategy, little was known in Iran 
about the level of pre-existing antibodies and immunity against the novel 2009 H1N1 
virus in the population which are considered to be the most important determining fac-
tors for the susceptibility of the community to S-OIV.  In this study, we aimed to meas-
ure, as a pilot study, the seroprevalence of the antibody titer (humoral immunity) against 
2009 H1N1 virus using HI assay in an Iranian population in Shiraz, southern Iran. 
 
 
MATERIALS AND METHODS 
 
Subjects and Sample Collection. Shiraz is the center of Fars province in southern Iran 
with a population of 1,300,000 in urban area and 600,000 in the rural part. For deter-
mining the seroprevalence of the protective antibodies in the community against 2009 
H1N1 in this city, we conducted a cross sectional study in December 2009 prior to the 
beginning of a vaccination program against this novel virus. 
Random clustered household family members, who lived either in urban or rural areas 
of Shiraz, were selected. After explaining the purpose of the study and filling the con-
sent forms, 2553 subjects were accepted to participate in this survey. Each individual 
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was then interviewed by a trained interviewer using a standard questionnaire regarding 
such demographic data as age, gender, residence and history of any sign or symptom of 
flu like illnesses in the past 6 months, history of vaccination against seasonal influenza 
or the history of any chronic medical condition.  
The pattern of age distribution of the family members was matched completely with the 
age distribution of the community. Finally blood samples were drawn from each indi-
vidual, kept on ice during transport to the laboratory, and centrifuged within 4 hours. 
Sera were separated and stored at -70˚C until tested. The study was conducted after the 
approval of the institutional ethical board review and the signed informed consent of 
each participant. 
Antigen Preparation. The influenza virus was isolated from throat swabs of patients for 
whom H1N1 infection was previously confirmed by polymerase chain reaction (PCR). 
Madin-Darby Canine Kidney (MDCK) cell monolayer was grown in Dulbecco’s modi-
fied Eagle’s medium (DMEM) (Sigma, St. Louis, MI) supplemented with 10% fetal bo-
vine serum (FBS) (Gibco, Gaithersburg, MD), 100 unit/ml penicillin G and 100µg/ml 
streptomycin and infected with the pharyngeal specimen and incubated at 34°C for 4 to 
5 days (9). Upon development of cytopathic effect, viral presence was shown by hem-
magglutination assay and real time PCR using specific 2009 H1N1 flu primer Taqman® 
Probes (Flu A, swine Flu A) (CDC protocol of real time RTPCR for H1N1 influenza 
A). 
Hemagglutination Inhibition Assay (HI). In this study HI assay was carried out ac-
cording to Suing method (10). Briefly, the patients’ sera were inactivated at 56°C for 30 
minutes, nonspecific inhibitors (11) and autohemagglutinins were then removed. Dou-
bling dilutions of sera (resulting in dilutions from 1:10 to 1:1,280) were made in 96 V 
shaped microplates. Twenty five microliters of a solution containing four HA units were 
added to each sera dilution and incubated at 37˚C for one hour. Then 50 microliters of 
guinea pig erythrocytes (0.5% v/v) were added to each well, and the results were re-
corded after one hour at 4˚C. The HA titer of each serum sample was determined to be 
the inverse of the last dilution where cells were not agglutinated. The antibody titer of 
1:40 or more was considered positive as reported in other studies (12-14)  
Statistical analysis. Categorical variables (sex, type of symptoms and age group) are 
described as count and percentages. The Fisher Exact test was used to compare the in-
dependent groups. When Categorical variables were described as proportions, χ2 test 
and Fisher Exact test were used for comparison. 
A two-sided p value less than 0.05 was considered statistically significant. To account 
for multiple comparisons performed in the analysis, p values were adjusted using per-
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Participation Rate and Demographic Data. The study was performed in December 
2009 in Shiraz and out of 2730 participants from 1 month to 87 years of age, inter-
viewed for the evidence of flu like illness during the past 6 months, where applicable. 
2553 (91%) had their sera tested for the presence of 2009 H1N1 novel virus antibody. 
Although all 2553 participants were tested for the presence of antibody, there were 
some missing demographic data due to incomplete filling of the questionnaires as de-
scribed in Table 1. The percentage of participants whose samples were tested did not 
 
H1N1 antibodies in Shiraz population 
vary by sex or education index. 37.4% (957) of the participants were male and out of 
1603 women who enrolled in this study, 41 (2.5%) were pregnant. 1952 (76.3%) cases 
were living in urban parts of Shiraz and the rest lived in rural areas. The complete 
demographic data of the participants is shown in Table 1. Only 96 (3.8%) subjects had a 
history of travelling abroad in the past 6 months out of which 61 travelled to either Iraq 
or Saudi Arabia (SA). 
 
Table 1. Summary of demographic data of the participants. 
 





- 1952 (76.3%) 




-   957 (37.4%) 
pregnancy 41 (2.5% of females) 
History of chronic illness 
- Asthma  
- Respiratory illness 
- Diabetes 
- HIV infection 
- Immune deficiency 
- Others 
602 (23.5%) 
-   56 (2.1%) 
-   27 (1%) 
-   83 (3.2%) 
-     1 (0.03%) 
-     4 (0.1%) 
- 431 (16.8%) 
Age Mean: 33.13 ± 18.41 
Min: 1  
Max: 87  
Level of education 
- Illiterate 
- high school 
- university graduate  
 
-   289 (11.3%) 
- 1916 (75.1%) 
-   348 (13.6%) 
History of seasonal flu vaccination     179 (7%) 
History of flu like illness in the last 6 months 
 
  1405 (54.9%) 
 
History of Tamiflu (Oseltamivir) ingestion      13 (0.5%) 
History of travelling abroad (last 6 months)      87 (3.4%) 
 
We also gathered information regarding the prior history of seasonal influenza vaccina-
tion. 179 (7%) of the cases had a history of receiving at least one dose of seasonal influ-
enza virus vaccine which in some cases dated back to the year 2004. Of these 179 sub-
jects, 153 were vaccinated for the first time during the year 2009. 
Regarding the history of flu like illness signs and symptoms, 1405 (54.9%) participants 
had experienced flu like symptoms such as fever, sore throat, cough, myalgia, etc. dur-
ing the past 6 months. However, only 13 (0.5%) cases had received Tamiflu for their 
symptoms as a treatment for pandemic flu. The most common complaints of those with 
a history of flu like illness during the course of the disease was sore throat (38.2%), 
cough (32.4%) and fever (28.3%), respectively. Diarrhea (3.4%) and vomiting (2.5%) 
were the least prevalent symptoms. 
Also 41 pregnant women and 602 subjects with chronic health conditions such as respi-
ratory, renal or liver illnesses, cancer, diabetes, etc. were enrolled in our survey. Among 
these patients, the overall percent of positive antibody was roughly 59.4% which was 
close to the percentage in the general population of the study (58.91%). 
Hemagglutination Inhibition Assay. As mentioned earlier, after performing the he-
magglutination inhibition assay on the sera, a 1:40 titer of antibody against 2009 H1N1 
virus was considered as the cut off point and therefore titers equal or greater than 40 
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were considered positive. Overall 1504 (58.91%) of the samples were tested positive for 
the antibody against 2009 H1N1 virus. Comparison of the rate of positive titers between 
those with a history of flu like illness in the past 6 months and those with no history of 
such symptoms showed no statistically significant difference (p=0.06). The prevalence 
rates of positive (>1:40) titer in the above groups were 58% (811) and 61.1% (697), re-
spectively. The serum titers had no statistically significant differences based on sex, 
level of education or other demographic data. 
All subjects were categorized into 12 groups based on their age. The results of the 
prevalence of positive titers of HA inhibition assay in each age group is presented in 
Table 2 and Figure 1. 
 
Table 2. Age distribution of serum antibody titers against 2009 H1N1 virus after 
application of hemagglutination inhibition assay. 
 
Hemagglutination Inhibition Assay results 
 











Total number of participants in 
age groups
N (% of total participants)
0-23 months 1.00±0.46 14 (60.87%) - 9 (39.1%) 23 (0.9%)
2-4 years 3.40±1.13 77 (57.04%) 10 (7.4%) 48 (35.6%) 135 (5.3%)
5-9 years 7.55±1.16 72 (55.81%) 6 (4.7%) 51 (39.5%) 129 (5.1%)
10-14 years 11.91±1.40 77 (52.74%) 13 (8.9%) 56 (38.4%) 146 (5.7%)
15-19 years 17.27±1.36 118 (64.84%) 14 (7.7%) 50 (27.5%) 182 (7.1%)
20-24 years 22.21±1.49 128 (47.76%) 19 (7.1%) 121 (45.1%) 268 (10.5%)
25-29 years 26.90±1.36 167 (58.39%) 19 (6.6%) 100 (35%) 286 (11.2%)
30-39 years 34.34±2.91 312 (60.58%) 34 (6.6%) 169 (32.8%) 515 (20.2%)
40-49 years 44.00±2.91 208 (59.43%) 20 (5.7%) 122 (34.9%) 350 (13.7%)
50-59 years 53.78±2.86 155 (59.16%) 26 (9.9%) 81 (30.9%) 262 (10.3%)
60-64 years 61.46±1.52 73 (78.49%) 6 (6.5%) 14 (15.1%) 93 (3.6%)
> 65 years 71.32±5.01 103 (62.80%) 10 (6.1%) 51 (31.1%) 164 (6.4%)
























Prevalence of serum positivity in 20 to 24 years old group was significantly lower than 
other age groups (p<0.05). Serum positivity was significantly higher in 60 to 64 years 
old group (p=0.001) compared to the other age groups. 
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Figure 1. Age distribution of 2553 subjects used in Shiraz sero-epidemiology study for Influenza 
A (H1N1) virus according to serum positivity (titer ≥ 1:40) for 2009 H1N1 virus. 
 
 
The detailed information regarding the prevalence of different serum titers are listed in 
Figure 2. 
The total of 2553 participants in the study group were categorized into 12 age groups 
consisting of: 23 cases in 0-1, 135 cases in 2-4, 129 cases in 5-9, 146 cases in 10-14, 
182 cases in 15-19, 268 cases in 20-24, 286 cases in 25-29, 515 cases in 30-39, 350 
cases in 40-49, 262 cases in 50-59, 93 cases in 60-64 and 164 cases in >65 years of age.  
The total numbers in some categories are different from each other due to some missing 





Figure 2. Quantification of serum antibody titers against 2009 H1N1 virus in an Iranian popula-
tion. A total of 2553 sera were tested using hemagglutination inhibition assay; titers equal or 
more than 1:40 were considered positive for antibody against 2009 H1N1 virus. 
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Since the outbreak of H1N1 influenza was considered pandemic, there has been debate 
whether it should be considered as a major health issue leading to high rates of mortality 
and morbidity; furthermore there has been concerns regarding the need for identification 
of the target groups for H1N1 virus vaccination (15). According to WHO latest data on 
H1N1 influenza, at least 13554 deaths related to 2009 H1N1 pandemic have been re-
ported and nearly 883 of them were reported from WHO Regional Office for the East-
ern Mediterranean (EMRO) (16). 
The report of the first confirmed cases of H1N1 flu in Iran has recently been published 
(17). Based on this study a total of 2662 cases of H1N1 flu were confirmed until No-
vember 2009, with 58 deaths. The results of this investigation revealed a rapid increase 
in the number of cases diagnosed as H1N1 flu in the consecutive months since the ap-
pearance of the disease in mid October. This raises another issue which is if H1N1 epi-
demic should be considered as a major health burden in Iran and if a concise and na-
tionwide vaccination strategy for the Iranian population has to be tailored.  
Based on the latest guidelines (18,19) and in the presence of resource limitations, prior-
ity for the vaccination against H1N1 virus should be considered for high risk groups in 
the following order: health care medical workers, pregnant women, individuals older 
than 6 months with severe chronic medical conditions such as lung disease or renal im-
pairment etc., healthy individuals aged 15 to 49 years, healthy children, healthy adults 
aged 50 to 64 years, and healthy adults older than 65 years. The mechanisms of protec-
tion against H1N1 influenza by vaccination are thought to be of humoral immunity and 
antibody formation against H1N1 virus (20). 
A number of investigators have supported these claims by the measurement of the hu-
moral immunity status of their population and the pre-existing antibody against H1N1. 
The results have revealed that while individuals older than 60 years had high levels of 
antibody against pandemic flu, probably due to previous exposures to this type of virus 
(such as 1918 pandemic flu), the younger population had a low or a negative titer of an-
tibody, posing their sensitivity to H1N1 infection. This necessitates the vaccination of 
younger groups and children (21-23). 
Hancock et al., (21) conducted a study to evaluate the immune status of different age 
groups against H1N1 influenza. While 39 (34%) unvaccinated subjects older than 60 
years had high titers (more than 1:40) of antibody against 2009 H1N1 virus, only 4 (4%) 
unvaccinated cases younger than 30 years had positive (1:40) titers of the antibody. An-
other report published by the Center for Disease Control and Prevention (CDC) demon-
strated that 33% of those older than 60 years had pre-existing neutralizing antibody 
against 2009 H1N1 virus in USA (12). 
These findings are in contrast to our results which revealed that 68.5% (176 out of 257) 
of the cases older than 60 years had a positive (1:40) titer against 2009 H1N1 virus and 
overall 58.91% (1504 subjects out of 2553) had a 1:40 positive titer of antibody against 
2009 H1N1 virus compared to the overall 11% of positive serum samples in the study 
done in USA (12). This high seroprevalence of positive antibody titers in Iranian sub-
jects is more notable when compared to the results of a survey in a Chinese population 
showing that out of 4043 subjects with no prior history of vaccination for Influenza vi-
rus, only 1.7% (70 serum samples) had positive (1:40) titers against this virus (13). The 
authors concluded that due to high prevalence of seronegative persons for H1N1 virus 
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in China, repeated vaccination is required for partial immunity against 2009 H1N1 vi-
rus. 
Altogether, data analysis of the pre-existing antibody against 2009 H1N1 virus suggests 
that a high level of immunity against 2009 H1N1 virus exists in Iranian population even 
in those with chronic illnesses. Not only the prevalence of immunity was high in the 
elderly but also similar results were observed in the younger groups and even children.  
There was no pre-existing cross-reactive antibody against 2009 H1N1 virus in children 
of 6 months to 9 years in the investigation of Hancock et al., (21), positive antibody 
titers were found in 60.87%, 57.04%, 55.81% of cases in the age groups of 1 to 23 
months, 2 to 5 years and 5 to 9 years, respectively. The high seroprevalence of positive 
titers of the antibody against H1N1 virus in our samples was also observed in other age 
groups either in elderly and adults or in younger groups or in children as shown in Fig-
ure 1. The prevalence of positive titers was significantly higher in 60 to 64 years old 
group (78.49%) compared to other groups (p=0.001) which agrees with similar findings 
by other investigators (11-13). Yet the percentage of positivity was interestingly higher 
in our findings compared to those of the same age group in similar studies. Seropositiv-
ity rate in the age group of over 65 years was significantly lower than the 60-64-year old 
group. Previous endemics have caused positivity in sera of over 60 year old individuals 
worldwide, however, the reason for higher prevalence of the antibody in 60 to 64 years 
old group compared to that of the older ones is not fully understood. Weaker immune 
system and decreased immune memory of the elderly may contribute to lower positivity 
rates in over 65 year old group.  
On the other hand the lowest rate of positive hemagglutination inhibition assay was ob-
served in the younger (20-24 years) age group (47.76%) which was significantly lower 
than other age groups (p<0.05). However, there was no statistically significant differ-
ence in the prevalence of positive titers among other age groups. Overall, even the low-
est seroprevalence of positive titers in our population was meaningfully higher than 
those of other groups (12,13).  
Additionally, even in those subjects with underlying diseases that categorized them as 
high risk individuals for H1N1 infection, the positive titer was seen in as high as 59.4%.  
This high level of positive antibody titer in the society and in different age groups which 
was of polyclonal B-cell nature can be interpreted by one of the following theories: 
One possibility is that 2009 H1N1 virus has caused considerable number of asympto-
matic infections in the population. Considering the fact that the prevalence of positive 
titers (≥1:40) did not differ in those with a history of flu like illness in the past 6 months 
and those with no history of any flu like illness symptom (58% compared to 61.1%, re-
spectively with a p value greater than 0.06), it can be hypothesized that asymptomatic 
infection with 2009 H1N1 virus or repeated previous encounters with a similar antigen 
might have played a role in high seroprevalence of 2009 H1N1 antibody in the sera of 
participants and therefore seroconversion after asymptomatic infection has produced a 
high prevalence of positive hemagglutination inhibition assay. 
However, higher rates of seropositivity in infants (0-23 month age group) cannot be 
simply elucidated by the presumption of prior asymptomatic infection. Although as-
ymptomatic infections can occur in this age group, usually there is a little chance that an 
infant or a newborn will be infected with influenza virus and develop seroprotection in 
such a short period. The high prevalence of seroprotection in infants in our study can 
also be explained by a possible maternal transfer of IgG against influenza virus during 
fetal life leading to the immunity in newborns and infants and a subsequent seroprotec-
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tion. This is further supported by the fact that a high prevalence of seropositivity was 
observed in other age groups including women in a child bearing age. However, the cer-
tainty of this claim should be further tested. 
It may also be hypothesized that there might be some form of innate or pre-existing 
immunity in the Iranian population that has resulted in such a high rate of seroprotection 
in all age groups and this also might be due to cross reactivity of the measured antibody 
to other forms of antibodies against influenza A viruses that might have been previously 
epidemic in Iran and has led to a significant protection in all age groups. However, all of 
these claims remain hypothetical and they should be investigated further although put-
ting such theories into test might not be easy or even possible. 
Furthermore, it should be kept in mind that the type of virus genome that was used was 
the one that caused the pandemic in Iran and might differ slightly in genomic structure 
from those in other parts of the world.  
It is also noteworthy that even though the polyclonal antibody that was measured and 
interacted with H1N1 virus is not specific for this serotype and surely has cross reactiv-
ity with other antibodies, yet the antibody creates at least some form of protection and 
cross-reactivity against the pandemic flu virus in individuals. It is well established that 
the humoral immunity and antibody titer against H1N1 virus correlates directly with a 
reduction of mortality and morbidity caused by pandemic flu (20). In fact serum anti-
body titer of 1:40 (used as the cut off point in this survey) is proven to be associated 
with a minimum of 50% decrease in the risk of influenza infection and the related mor-
tality rates (14). Based on this fact and the results of the present study, it can be hy-
pothesized that pandemic flu might really not be as dangerous as it was previously 
thought, at least in Iranian population, due to a high level of effective antibody titer 
(1:40) against 2009 H1N1 virus in the sera of different age groups. The appropriateness 
of setting the cutoff point at 1:40 antibody titer for the determination of seropositivity 
and protection in this study was also supported by other similar investigations (12-
14,24). The fact that we observe a fewer number of hospitalized cases of pandemic flu 
than what was expected based on worldwide estimates supports this theory. Based on 
the latest modeling for pandemic flu, it is predicted that the number of hospitalized 
cases due to pandemic flu will be at least 0.5% to 1.5% of the outpatient presentations 
of 2009 H1N1 flu in the community (25,26). The current numbers of hospitalization and 
case fatalities in Iran are far less than what was predicted by these models (17). On the 
other hand, due to the limited availability of H1N1 vaccine worldwide, countries have 
chosen different strategies on vaccination. For example, Chinese government has tar-
geted only 5% of its population for the first phase of vaccination, while Canada has 
planned a nationwide program to cover 100% of its population (27). In our country 
there are debates regarding identification of target groups for vaccination. Considering 
the high prevalence of pre-existing immunity in our population on one hand (approxi-
mately overall 60% positive titer against H1N1 virus) and the limited resources for pro-
viding the vaccine on the other hand, mass vaccination against H1N1 virus does not 
seem reasonable or cost-effective. Even the need for vaccination of high risk groups 
such as those with chronic underlying illnesses or the elderly or even young adults and 
children should be re-evaluated since they all demonstrated high levels of positive titers 
against 2009 H1N1 virus in our investigation. Therefore, the existing guidelines for tar-
geting high risk groups for vaccination do not apply to our community. Yet, in order to 
be able to design an accurate strategy for vaccination or the management of a pandemic 
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